Table 3 Reasons for end-of-life decisions in patients dying from cancer (n = 963)

From: End-of-life decision-making across cancer types: results from a nationwide retrospective survey among treating physicians

Reasons for ELD

 

Physical suffering

No prospect of improvement

Wish of the patient

Expected further suffering

Life not to be prolonged needlessly

Expected poor quality of life

Wish of the family

Loss-of-dignity

Mental suffering

Unbearable situation for relatives

Cancer type

Weighted %a

All cancer deaths for which at least one ELD was made (n = 963)

76.8

66.9

43.0

38.6

38.4

36.5

28.0

21.9

21.5

12.4

Gastrointestinal (n = 291)

71.8

65.1

41.9

35.8

32.1

37.4

23.8

21.6

19.6

10.5

Respiratory (n = 233)

78.9

70.0

46.2

43.4

42.7

40.9

29.5

18.6

22.6

10.8

Genitourinary (n = 178)

79.9

62.7

40.4

34.3

43.4

35.6

29.2

25.1

20.7

10.9

Breast (n = 71)

87.0

72.4

45.4

48.5

29.7

31.5

30.3

25.5

32.6

10.4

Haematological (n = 68)

71.0

78.6

45.9

53.8

43.5

46.1

25.5

24.8

23.9

23.4

Otherb (n = 122)

77.5

60.4

40.0

26.0

39.2

23.0

33.4

20.5

17.3

16.9

P-valuec

.115

.130

.853

.003

.098

.034

.559

.723

.322

.054

  1. Concerns the most important ELD. More than one reason was possible for each case
  2. Percentages are row percentages ELD end-of-life decision with possible or certain life-shortening effect
  3. Not included in table and analyses: ‘other’ category reasons for ELDs n = 15 (1.6% of all cancer deaths for which at least one ELD was made), missing data for reasons for ELDs n = 77 (8.0% of all cancer deaths for which at least one ELD was made)
  4. aPercentages are weighted for the disproportionate stratification and differences in the distribution of mortality characteristics between the response sample and all patient deaths
  5. b‘Other’ category includes head and neck; bone and articular cartilage; skin; eye, brain, and central nervous system; thyroid and endocrine glands; ill-defined, secondary and unspecified sites; independent (primary) multiple sites
  6. cBivariate differences between patients with different cancer types calculated using Pearson’s χ2-tests. Bold denotes significance at p < .05